Santhosh Kumar Bangalore Vasantha Kumar, MD
Allergy & Immunology · Atlanta, GANPI 1568639466
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,826 of the $10,675 with a category attached, or 73.3%. Biocryst Pharmaceuticals, Inc. accounts for 65.5% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $7,092, more than ten times the $95 reported in 2019.
Across 29 payments — averaging $368.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocryst Pharmaceuticals, Inc.$7K
- Biocryst US Sales Co., LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Regeneron Healthcare Solutions, Inc.$465
- AstraZeneca$368
- Sanofi$225
- plus $95 from 1 others
Across 10 payments — averaging $4915.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$49K
What the payments were for
- Consulting fees$7,82673%
- Travel & lodging$1,38913%
- Food & beverage$1,46014%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocryst Pharmaceuticals, Inc. | 14 | $6,990 |
| Biocryst US Sales Co., LLC | 2 | $1,407 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,125 |
| Regeneron Healthcare Solutions, Inc. | 5 | $465 |
| AstraZeneca | 4 | $368 |
| Sanofi | 2 | $225 |
| Johnson & Johnson | 1 | $95 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,675 in reported general payments places this provider in the 70th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 13 | $326,537 |
| NucalaMepolizumab | 14 | $96,323 |
| XolairOmalizumab | 18 | $73,027 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $59,550 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 22 | $44,981 |
| Epinephrine | 18 | $3,891 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,745 |
| Azithromycin | 31 | $486 |
| Azelastine Hcl | 11 | $397 |
| Ipratropium Bromide | 13 | $348 |
| Fluticasone Propionate | 13 | $275 |
| Montelukast Sodium | 15 | $61 |
| Sodium Chloride0.9 % Sodium Chloride | 13 | $50 |
| Prednisone | 15 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $1,125 | $326,53713 claims |
| AstraZenecaSymbicort | $368 | $2,74512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Atlanta
- Deborah BirxAtlanta$470K
- Paul RabinowitzAtlanta$57K
- Gerald LeeAtlanta$52K
- Luqman SeiduAtlanta$32K
- Alan ReddingAtlanta$23K
- David ReddingAtlanta$22K
- Merin KalangaraAtlanta$19K
- Glen NadelAtlanta$12K
- Keith LenchnerAtlanta$11K
- David TannerAtlanta$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.